Literature DB >> 11752399

Increased insulin sensitivity in mice lacking p85beta subunit of phosphoinositide 3-kinase.

Kohjiro Ueki1, Claudine M Yballe, Saskia M Brachmann, David Vicent, John M Watt, C Ronald Kahn, Lewis C Cantley.   

Abstract

On the basis of ex vivo studies using insulin-responsive cells, activation of a Class IA phosphoinositide 3-kinase (PI3K) seems to be required for a wide variety of cellular responses downstream of insulin. The Class IA PI3K enzymes are heterodimers of catalytic and regulatory subunits. In mammals, insulin-responsive tissues express both the p85alpha and p85beta isoforms of the regulatory subunit. Surprisingly, recent studies have revealed that disruption of the p85alpha gene in the mouse (p85alpha(-/-) mice) results in hypoglycemia with decreased plasma insulin, and the p85alpha(+/-) mice exhibit significantly increased insulin sensitivity. These results suggest either that p85alpha negatively regulates insulin signaling, or that p85beta, which mediates the major fraction of Class IA PI3K signaling in the absence of p85alpha, is more efficient than p85alpha in mediating insulin responses. To address this question, we have generated mice in which the p85beta gene is deleted (p85beta(-/-) mice). As with the p85alpha(-/-) mice, the p85beta(-/-) mice showed hypoinsulinemia, hypoglycemia, and improved insulin sensitivity. At the molecular level, PI3K activity associated with phosphotyrosine complexes was preserved despite a 20-30% reduction in the total protein level of the regulatory subunits. Moreover, insulin-induced activation of AKT was significantly up-regulated in muscle from the p85beta(-/-) mice. In addition, insulin-dependent tyrosine phosphorylation of insulin receptor substrate-2 was enhanced in the p85beta(-/-) mice, a phenotype not observed in the p85alpha(-/-) mice. These results indicate that in addition to their roles in recruiting the catalytic subunit of PI3K to the insulin receptor substrate proteins, both p85alpha and p85beta play negative roles in insulin signaling.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11752399      PMCID: PMC117575          DOI: 10.1073/pnas.012581799

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  37 in total

1.  Tissue-specific knockout of the insulin receptor in pancreatic beta cells creates an insulin secretory defect similar to that in type 2 diabetes.

Authors:  R N Kulkarni; J C Brüning; J N Winnay; C Postic; M A Magnuson; C R Kahn
Journal:  Cell       Date:  1999-02-05       Impact factor: 41.582

2.  IRS-1 activates phosphatidylinositol 3'-kinase by associating with src homology 2 domains of p85.

Authors:  M G Myers; J M Backer; X J Sun; S Shoelson; P Hu; J Schlessinger; M Yoakim; B Schaffhausen; M F White
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205

3.  SH2 domains recognize specific phosphopeptide sequences.

Authors:  Z Songyang; S E Shoelson; M Chaudhuri; G Gish; T Pawson; W G Haser; F King; T Roberts; S Ratnofsky; R J Lechleider
Journal:  Cell       Date:  1993-03-12       Impact factor: 41.582

4.  Essential role of phosphatidylinositol 3-kinase in insulin-induced glucose transport and antilipolysis in rat adipocytes. Studies with a selective inhibitor wortmannin.

Authors:  T Okada; Y Kawano; T Sakakibara; O Hazeki; M Ui
Journal:  J Biol Chem       Date:  1994-02-04       Impact factor: 5.157

5.  Increased insulin sensitivity and hypoglycaemia in mice lacking the p85 alpha subunit of phosphoinositide 3-kinase.

Authors:  Y Terauchi; Y Tsuji; S Satoh; H Minoura; K Murakami; A Okuno; K Inukai; T Asano; Y Kaburagi; K Ueki; H Nakajima; T Hanafusa; Y Matsuzawa; H Sekihara; Y Yin; J C Barrett; H Oda; T Ishikawa; Y Akanuma; I Komuro; M Suzuki; K Yamamura; T Kodama; H Suzuki; K Yamamura; T Kodama; H Suzuki; S Koyasu; S Aizawa; K Tobe; Y Fukui; Y Yazaki; T Kadowaki
Journal:  Nat Genet       Date:  1999-02       Impact factor: 38.330

6.  Impaired B cell development and proliferation in absence of phosphoinositide 3-kinase p85alpha.

Authors:  D A Fruman; S B Snapper; C M Yballe; L Davidson; J Y Yu; F W Alt; L C Cantley
Journal:  Science       Date:  1999-01-15       Impact factor: 47.728

Review 7.  Protein kinase B (c-Akt): a multifunctional mediator of phosphatidylinositol 3-kinase activation.

Authors:  P J Coffer; J Jin; J R Woodgett
Journal:  Biochem J       Date:  1998-10-01       Impact factor: 3.857

8.  Requirement of atypical protein kinase clambda for insulin stimulation of glucose uptake but not for Akt activation in 3T3-L1 adipocytes.

Authors:  K Kotani; W Ogawa; M Matsumoto; T Kitamura; H Sakaue; Y Hino; K Miyake; W Sano; K Akimoto; S Ohno; M Kasuga
Journal:  Mol Cell Biol       Date:  1998-12       Impact factor: 4.272

Review 9.  Phosphoinositide 3-kinase: the key switch mechanism in insulin signalling.

Authors:  P R Shepherd; D J Withers; K Siddle
Journal:  Biochem J       Date:  1998-08-01       Impact factor: 3.857

10.  Phosphatidylinositol 3'-kinase is activated by association with IRS-1 during insulin stimulation.

Authors:  J M Backer; M G Myers; S E Shoelson; D J Chin; X J Sun; M Miralpeix; P Hu; B Margolis; E Y Skolnik; J Schlessinger
Journal:  EMBO J       Date:  1992-09       Impact factor: 11.598

View more
  82 in total

Review 1.  Tissue-specific targeting of the insulin receptor gene.

Authors:  Rohit N Kulkarni; Terumasa Okada
Journal:  Endocrine       Date:  2002-12       Impact factor: 3.633

2.  Hyperinsulinemia, glucose intolerance, and dyslipidemia induced by acute inhibition of phosphoinositide 3-kinase signaling in the liver.

Authors:  Kazuaki Miyake; Wataru Ogawa; Michihiro Matsumoto; Takehiro Nakamura; Hiroshi Sakaue; Masato Kasuga
Journal:  J Clin Invest       Date:  2002-11       Impact factor: 14.808

3.  The phosphoinositide 3-kinase regulatory subunit p85alpha can exert tumor suppressor properties through negative regulation of growth factor signaling.

Authors:  Cullen M Taniguchi; Jonathon Winnay; Tatsuya Kondo; Roderick T Bronson; Alexander R Guimaraes; José O Alemán; Ji Luo; Gregory Stephanopoulos; Ralph Weissleder; Lewis C Cantley; C Ronald Kahn
Journal:  Cancer Res       Date:  2010-06-08       Impact factor: 12.701

4.  PI3K-p110α mediates the oncogenic activity induced by loss of the novel tumor suppressor PI3K-p85α.

Authors:  Lauren M Thorpe; Jennifer M Spangle; Carolynn E Ohlson; Hailing Cheng; Thomas M Roberts; Lewis C Cantley; Jean J Zhao
Journal:  Proc Natl Acad Sci U S A       Date:  2017-06-19       Impact factor: 11.205

5.  PI3Kα inactivation in leptin receptor cells increases leptin sensitivity but disrupts growth and reproduction.

Authors:  David Garcia-Galiano; Beatriz C Borges; Jose Donato; Susan J Allen; Nicole Bellefontaine; Mengjie Wang; Jean J Zhao; Kenneth M Kozloff; Jennifer W Hill; Carol F Elias
Journal:  JCI Insight       Date:  2017-12-07

6.  Mice Carrying a Dominant-Negative Human PI3K Mutation Are Protected From Obesity and Hepatic Steatosis but Not Diabetes.

Authors:  Marie H Solheim; Jonathon N Winnay; Thiago M Batista; Anders Molven; Pål R Njølstad; C Ronald Kahn
Journal:  Diabetes       Date:  2018-05-03       Impact factor: 9.461

Review 7.  PI3K signaling in glioma--animal models and therapeutic challenges.

Authors:  Christine K Cheng; Qi-Wen Fan; William A Weiss
Journal:  Brain Pathol       Date:  2009-01       Impact factor: 6.508

8.  The PTEN/PI3K pathway governs normal vascular development and tumor angiogenesis.

Authors:  Koichi Hamada; Takehiko Sasaki; Pandelakis A Koni; Miyuki Natsui; Hiroyuki Kishimoto; Junko Sasaki; Nobuyuki Yajima; Yasuo Horie; Go Hasegawa; Makoto Naito; Jun-Ichi Miyazaki; Toshio Suda; Hiroshi Itoh; Kazuwa Nakao; Tak Wah Mak; Toru Nakano; Akira Suzuki
Journal:  Genes Dev       Date:  2005-08-17       Impact factor: 11.361

9.  Class IA phosphoinositide 3-kinases are obligate p85-p110 heterodimers.

Authors:  Barbara Geering; Pedro R Cutillas; Gemma Nock; Severine I Gharbi; Bart Vanhaesebroeck
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-30       Impact factor: 11.205

Review 10.  The PI3K pathway as drug target in human cancer.

Authors:  Kevin D Courtney; Ryan B Corcoran; Jeffrey A Engelman
Journal:  J Clin Oncol       Date:  2010-01-19       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.